Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$301.94 USD

301.94
2,316,263

+5.06 (1.70%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $302.01 +0.07 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Mark Vickery headshot

Top Stock Reports for Chevron, Amgen & Thermo Fisher

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including Chevron (CVX), Amgen (AMGN), and Thermo Fisher (TMO).

    Zacks Equity Research

    Is Amgen (AMGN) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (AMGN) Outperforming Other Medical Stocks This Year?

      Zacks Equity Research

      Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality

      by Zacks Equity Research

      Eli Lilly's (LLY) CGRP antibody Emgality injection gains an FDA approval for the preventive treatment of migraine in adults.

        Zacks Equity Research

        Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks

        by Zacks Equity Research

        Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa.

          Zacks Equity Research

          Mylan's Biosimilar of Neulasta Gets Positive CHMP Opinion

          by Zacks Equity Research

          Mylan (MYL) gets a positive CHMP opinion for Fulphila, a proposed biosimilar of Amgen's Neulasta.

            Zacks Equity Research

            Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion

            by Zacks Equity Research

            Eli Lilly's (LLY) CGRP antibody Emgality gains a positive view from CHMP for the treatment of migraine in adults, who encounter minimum four migraine spells a month.

              Zacks Equity Research

              Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again

              by Zacks Equity Research

              Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                Zacks Equity Research

                Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status

                by Zacks Equity Research

                Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.

                  Zacks Equity Research

                  AbbVie Faces California Insurance Department Suit for Humira

                  by Zacks Equity Research

                  AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.

                    Zacks Equity Research

                    AstraZeneca's Fasenra Long-Term Asthma Study Data Positive

                    by Zacks Equity Research

                    AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.

                      Zacks Equity Research

                      The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

                        Zacks Equity Research

                        Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval

                        by Zacks Equity Research

                        Teva Pharmaceutical's (TEVA) anti-CGRP drug, Ajovy, gets FDA nod as a preventive treatment of migraine in adult patients.

                          Zacks Equity Research

                          Allergan Frown Lines Study Passes Test on Higher Botox Dose

                          by Zacks Equity Research

                          Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.

                            Mark Vickery headshot

                            Top Research Reports for UnitedHealth, Adobe & Amgen

                            by Mark Vickery

                            Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Adobe (ADBE) and Amgen (AMGN).

                              Zacks Equity Research

                              Is Amgen (AMGN) a Great Stock for Value Investors?

                              by Zacks Equity Research

                              Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

                                Zacks Equity Research

                                Merck Gets Priority Review for Yet Another Keytruda sBLA

                                by Zacks Equity Research

                                Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.

                                  Zacks Equity Research

                                  Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA

                                  by Zacks Equity Research

                                  The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.

                                    Zacks Equity Research

                                    3 Small Biotech Stocks That Almost Doubled in Past Month

                                    by Zacks Equity Research

                                    We take a look at three biotech stocks, prices of which have almost doubled in the past month.

                                      Zacks Equity Research

                                      Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe

                                      by Zacks Equity Research

                                      Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.

                                        Zacks Equity Research

                                        AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status

                                        by Zacks Equity Research

                                        AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.

                                          Kinjel Shah headshot

                                          Lilly, Teva, Pfizer & Others Await FDA Decisions in September

                                          by Kinjel Shah

                                          FDA grants approval to 34 new treatments this year so far.

                                            Zacks Equity Research

                                            Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status

                                            by Zacks Equity Research

                                            Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.

                                              Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

                                              by Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

                                                Zacks Equity Research

                                                Merck's Keytruda Gets Priority Review for Rare Skin Cancer

                                                by Zacks Equity Research

                                                Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.

                                                  Zacks Equity Research

                                                  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

                                                  by Zacks Equity Research

                                                  Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.